{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:28:19Z","timestamp":1787927299018,"version":"build-2784847793"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Mansoura Ufig. 4niversity"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic kidney disease (CKD) is a top public health priority and global health concern. Owing to the buildup of toxins and the decreased removal of inflammatory mediators, the illness frequently causes inflammation, which eventually impairs kidney function. This study sought to provide insight into the potential prophylactic effect of febuxostat against adenine-induced CKD. Rats were distributed into 4 groups; normal, adenine (200\u00a0mg\/kg, orally, once daily) and febuxostat groups (rats received either 5 or 15\u00a0mg\/kg of febuxostat concurrently with adenine). Febuxostat effectively attenuated adenine-induced CKD as manifested by marked drop in serum creatinine, BUN, proteinuria and rise in creatinine clearance. Histopathological analysis supported these biochemical results. Moreover, reduced MDA and increased GSH levels indicate that febuxostat restored the oxidant\/antioxidant equilibrium. Additionally, febuxostat in both doses reduced inflammation as evidenced by reduced renal expression of TLR4 and NF-\u03baB besides reduced renal levels of NLRP3, Caspase1, IL-1\u03b2 and TNF-\u03b1. Collectively, febuxostat efficiently attenuated adenine-induced CKD via down-regulating TLR4\/NF-\u03baB\/NLRP3\/Caspase1\/IL-1\u03b2 signaling pathway. Thus, febuxostat could be beneficial in clinical use against CKD pending further analysis.<\/jats:p>","DOI":"10.1007\/s10787-026-02308-0","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:39:47Z","timestamp":1783737587000},"page":"5823-5833","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Febuxostat attenuates chronic kidney disease induced by adenine in rats: role of TLR4\/NF-\u03baB\/NLRP3\/Caspase1\/IL-1\u03b2 pathway"],"prefix":"10.1007","volume":"34","author":[{"given":"Omnia A.","family":"Nour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M.","family":"Samaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitham M.","family":"Sewilam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia H.","family":"El-Kashef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"issue":"1","key":"2308_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.33594\/000000003","volume":"52","author":"BH Ali","year":"2019","unstructured":"Ali BH et al (2019) Effects of the SGLT-2 inhibitor canagliflozin on adenine-induced chronic kidney disease in rats. Cell Physiol Biochem 52(1):27\u201339","journal-title":"Cell Physiol Biochem"},{"issue":"5","key":"2308_CR2","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2017.12.007","volume":"72","author":"LP Gregg","year":"2018","unstructured":"Gregg LP, Hedayati SS (2018) Management of traditional cardiovascular risk factors in CKD: What are the data? Am J Kidney Dis 72(5):728\u2013744","journal-title":"Am J Kidney Dis"},{"issue":"1\u20132","key":"2308_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ddmod.2010.08.002","volume":"7","author":"HC Yang","year":"2010","unstructured":"Yang HC, Zuo Y, Fogo AB (2010) Models of chronic kidney disease. Drug Discov Today Dis Models 7(1\u20132):13\u201319","journal-title":"Drug Discov Today Dis Models"},{"issue":"1","key":"2308_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/bcpt.12817","volume":"122","author":"BH Ali","year":"2018","unstructured":"Ali BH et al (2018) Curcumin ameliorates kidney function and oxidative stress in experimental chronic kidney disease. Basic Clin Pharmacol Toxicol 122(1):65\u201373","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2308_CR5","doi-asserted-by":"publisher","first-page":"175731","DOI":"10.1016\/j.ejphar.2023.175731","volume":"949","author":"P Patel","year":"2023","unstructured":"Patel P et al (2023) Roflumilast alleviates adenine-induced chronic kidney disease by regulating inflammatory biomarkers. Eur J Pharmacol 949:175731","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"2308_CR6","first-page":"230","volume":"44","author":"T Yokozawa","year":"1986","unstructured":"Yokozawa T et al (1986) Animal model of adenine-induced chronic renal failure in rats. Nephron 44(3):230\u2013234","journal-title":"Nephron"},{"issue":"2","key":"2308_CR7","doi-asserted-by":"publisher","first-page":"e55242","DOI":"10.1371\/journal.pone.0055242","volume":"8","author":"BH Ali","year":"2013","unstructured":"Ali BH et al (2013) Effect of gum arabic on oxidative stress and inflammation in adenine-induced chronic renal failure in rats. PLoS ONE 8(2):e55242","journal-title":"PLoS ONE"},{"key":"2308_CR8","first-page":"101417","volume":"33","author":"G Huang","year":"2023","unstructured":"Huang G et al (2023) Chronic kidney disease and NLRP3 inflammasome: pathogenesis, development and targeted therapeutic strategies. Biochem Biophys Rep 33:101417","journal-title":"Biochem Biophys Rep"},{"issue":"1","key":"2308_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2174\/187221307779815020","volume":"1","author":"KH Yu","year":"2007","unstructured":"Yu KH (2007) Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. Recent Pat Inflamm Allergy Drug Discov 1(1):69\u201375","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"issue":"1","key":"2308_CR10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2174\/1871523011312010011","volume":"12","author":"J Sab\u00e1n-Ruiz","year":"2013","unstructured":"Sab\u00e1n-Ruiz J et al (2013) Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation. Antiinflamm Antiallergy Agents Med Chem 12(1):94\u201399","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"issue":"4","key":"2308_CR11","doi-asserted-by":"publisher","first-page":"p69","DOI":"10.1159\/000127837","volume":"108","author":"LG S\u00e1nchez-Lozada","year":"2008","unstructured":"S\u00e1nchez-Lozada LG et al (2008) Effect of febuxostat on the progression of renal disease in 5\/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol 108(4):p69\u201378","journal-title":"Nephron Physiol"},{"issue":"2","key":"2308_CR12","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.bbrc.2012.09.032","volume":"427","author":"H Tsuda","year":"2012","unstructured":"Tsuda H et al (2012) Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. Biochem Biophys Res Commun 427(2):266\u2013272","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"2308_CR13","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10157-012-0609-3","volume":"16","author":"H Omori","year":"2012","unstructured":"Omori H et al (2012) Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. Clin Exp Nephrol 16(4):549\u2013556","journal-title":"Clin Exp Nephrol"},{"key":"2308_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejphar.2017.02.046","volume":"805","author":"A Khames","year":"2017","unstructured":"Khames A et al (2017) Ameliorative effects of sildenafil and\/or febuxostat on doxorubicin-induced nephrotoxicity in rats. Eur J Pharmacol 805:118\u2013124","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2308_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4103\/mmj.mmj_167_19","volume":"34","author":"M El-Batsh","year":"2021","unstructured":"El-Batsh M et al (2021) Nephroprotective effect of coadministration of curcumin and sildenafil in adenine-induced chronic renal failure in rats. Menoufia Med J 34(1):297\u2013304","journal-title":"Menoufia Med J"},{"issue":"20","key":"2308_CR16","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1042\/CS20210405","volume":"135","author":"D Xu","year":"2021","unstructured":"Xu D et al (2021) Xanthine oxidase inhibitor febuxostat reduces atrial fibrillation susceptibility by inhibition of oxidized CaMKII in Dahl salt-sensitive rats. Clin Sci 135(20):2409\u20132422","journal-title":"Clin Sci"},{"key":"2308_CR17","doi-asserted-by":"publisher","first-page":"105580","DOI":"10.1016\/j.ejps.2020.105580","volume":"156","author":"AE Amer","year":"2021","unstructured":"Amer AE et al (2021) Febuxostat attenuates vascular calcification induced by vitamin D3 plus nicotine in rats. Eur J Pharm Sci 156:105580","journal-title":"Eur J Pharm Sci"},{"key":"2308_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248\u2013254","journal-title":"Anal Biochem"},{"issue":"5","key":"2308_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0928-4346(96)00256-3","volume":"4","author":"T Masuda","year":"1996","unstructured":"Masuda T et al (1996) Distinguishing small lymph vessels in the portal tracts of human liver from portal veins by immunohistochemistry for \u03b1 smooth muscle actin. Int Hepatol Commun 4(5):277\u2013282","journal-title":"Int Hepatol Commun"},{"key":"2308_CR20","doi-asserted-by":"publisher","first-page":"122080","DOI":"10.1016\/j.lfs.2023.122080","volume":"331","author":"MM Samaha","year":"2023","unstructured":"Samaha MM et al (2023) Diacerein mitigates adenine-induced chronic kidney disease in rats: focus on TLR4\/MYD88\/TRAF6\/NF-\u03baB pathway. Life Sci 331:122080","journal-title":"Life Sci"},{"key":"2308_CR21","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.biopha.2018.11.117","volume":"110","author":"AM Abdelrahman","year":"2019","unstructured":"Abdelrahman AM et al (2019) The renoprotective effect of the dipeptidyl peptidase-4 inhibitor sitagliptin on adenine-induced kidney disease in rats. Biomed Pharmacother 110:667\u2013676","journal-title":"Biomed Pharmacother"},{"issue":"67","key":"2308_CR22","doi-asserted-by":"publisher","first-page":"111295","DOI":"10.18632\/oncotarget.22784","volume":"8","author":"L He","year":"2017","unstructured":"He L et al (2017) Febuxostat attenuates ER stress mediated kidney injury in a rat model of hyperuricemic nephropathy. Oncotarget 8(67):111295\u2013111308","journal-title":"Oncotarget"},{"issue":"1","key":"2308_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/nep.13180","volume":"23","author":"V Diwan","year":"2018","unstructured":"Diwan V, Brown L, Gobe GC (2018) Adenine-induced chronic kidney disease in rats. Nephrol (Carlton) 23(1):5\u201311","journal-title":"Nephrol (Carlton)"},{"issue":"1","key":"2308_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.acthis.2003.08.001","volume":"106","author":"T Ardan","year":"2004","unstructured":"Ardan T, Kovaceva J, Cejkov\u00e1 J (2004) Comparative histochemical and immunohistochemical study on xanthine oxidoreductase\/xanthine oxidase in mammalian corneal epithelium. Acta Histochem 106(1):69\u201375","journal-title":"Acta Histochem"},{"issue":"2","key":"2308_CR25","doi-asserted-by":"publisher","first-page":"c97","DOI":"10.1159\/000324765","volume":"119","author":"J Lepenies","year":"2011","unstructured":"Lepenies J et al (2011) Renal TLR4 mRNA expression correlates with inflammatory marker MCP-1 and profibrotic molecule TGF-\u03b2\u2081 in patients with chronic kidney disease. Nephron Clin Pract 119(2):c97\u2013c104","journal-title":"Nephron Clin Pract"},{"key":"2308_CR26","doi-asserted-by":"publisher","first-page":"177873","DOI":"10.1016\/j.ejphar.2025.177873","volume":"1002","author":"AG Sakr","year":"2025","unstructured":"Sakr AG, Kafl HE, El-Kashef DH (2025) Rupatadine modulates TLR4\/MYD88\/NF-\u03baB and AKT\/PI3K signaling pathways, attenuating sepsis-induced liver injury in mice. Eur J Pharmacol 1002:177873","journal-title":"Eur J Pharmacol"},{"key":"2308_CR27","doi-asserted-by":"crossref","unstructured":"Balaha MF et al (2023) Shikonin Alleviates Gentamicin-Induced Renal Injury in Rats by Targeting Renal Endocytosis, SIRT1\/Nrf2\/HO-1, TLR-4\/NF-\u03baB\/MAPK, and PI3K\/Akt Cascades. Antibiotics (Basel), 12(5)","DOI":"10.3390\/antibiotics12050826"},{"issue":"5","key":"2308_CR28","doi-asserted-by":"publisher","first-page":"822","DOI":"10.3109\/0886022X.2016.1143757","volume":"38","author":"Z Chen","year":"2016","unstructured":"Chen Z et al (2016) Ozone therapy ameliorates tubulointerstitial inflammation by regulating TLR4 in adenine-induced CKD rats. Ren Fail 38(5):822\u2013830","journal-title":"Ren Fail"},{"key":"2308_CR29","doi-asserted-by":"crossref","unstructured":"Tian J, Zhang S (2023) Febuxostat ameliorates APAP-induced acute liver injury by activating Keap1\/Nrf2 and inhibiting TLR4\/NF-\u03baB p65 pathways. 248(20):1864\u20131876","DOI":"10.1177\/15353702231211862"},{"key":"2308_CR30","doi-asserted-by":"crossref","unstructured":"Zaafar D, Khalil HMA, Rasheed RA (2022) Hesperetin mitigates sorafenib-induced cardiotoxicity in mice through inhibition of the TLR4\/NLRP3 signaling pathway. 17(8):e0271631","DOI":"10.1371\/journal.pone.0271631"},{"key":"2308_CR31","doi-asserted-by":"publisher","first-page":"p111010","DOI":"10.1016\/j.intimp.2023.111010","volume":"124Pt B","author":"X Tian","year":"2023","unstructured":"Tian X et al (2023) Butyrate alleviates renal fibrosis in CKD by regulating NLRP3-mediated pyroptosis via the STING\/NF-\u03baB\/p65 pathway. Int Immunopharmacol 124Pt B:p111010","journal-title":"Int Immunopharmacol"},{"key":"2308_CR32","doi-asserted-by":"crossref","unstructured":"Abdel-Wahab BA et al (2023) Febuxostat alleviates Arsenic Trioxide-Induced renal injury in Rats: Insights on the crosstalk between NLRP3\/TLR4, Sirt-1\/NF-\u03baB\/TGF-\u03b2 signaling Pathways, and miR-23b-3p, miR-181a-5b expression. Biochem Pharmacol, 216: p. 115794","DOI":"10.1016\/j.bcp.2023.115794"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02308-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-026-02308-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02308-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:43:17Z","timestamp":1787924597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-026-02308-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2308"],"URL":"https:\/\/doi.org\/10.1007\/s10787-026-02308-0","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}